Radiation Therapy-Related Toxicity: Esophagus

  • Maria Werner-Wasik
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)


Radiat Oncol Biol Phys Radiation Therapy Oncology Group Common Toxicity Criterion Acute Esophagitis Esophagitis Grade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C, et al. (2001) Randomized Phase III trial of radiation treatment plus/minus amifostine in patients with advanced stage lung cancer. Int J Radiat Oncol Biol Phys 51:915–22Google Scholar
  2. Antonadou D (2002) Radiotherapy or chemotherapy fol lowed by radiotherapy with or without amifostine in locally advanced long cancer. Semin Radiation Oncol 12(suppl 1):50–8CrossRefGoogle Scholar
  3. Ball D, Bishop J, Smith J, Crennan E, O'Brien P, Davis S, et al. (1995) A Phase III study of accelerated radiotherapy with and without carboplatin in non small cell lung cancer: An interim toxicity analysis of the first 100 patients. Int. J. Radiat Oncol Biol. Phys 31:267–72CrossRefPubMedGoogle Scholar
  4. Boal DK, Newburger PE and Teele RL (1979) Esophagitis induced by combined radiation and Adriamycin. AJR 132:567–70PubMedGoogle Scholar
  5. Bradley JD, Graham MV, Winter KW, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B (2003) Acute and late toxicity results of RTOG 9311: A dose escalation study using conformal 3D radiation therapy in patients with inoperable non small cell lung cancer. Int J Radiation Oncol Phys 57[Suppl]:S137, abstr #23CrossRefGoogle Scholar
  6. Brizel DM, Wasserman TH, Henke M, Strnad V, Monnier A, Eschwege F, et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339–45PubMedGoogle Scholar
  7. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, et al. (1998) Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiation Oncology Biol Phys 42:469–78Google Scholar
  8. Choy H, LaPorte K, Knill-Selby E, Mohr P and Shyr Y (1999) Esophagitis in combined modality therapy for locally advanced non small cell lung cancer. Sem Rad Oncol 9:90–6Google Scholar
  9. Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, et al. (1993) Interruptions of high dose radiation therapy decrease long term survival of favorable patients with unresectable non small cell carcinoma of the lung: Analysis of 1244 cases from 3 RTOG trials, Int J Radiation Oncology Biol Phys 27:493–8Google Scholar
  10. Curran W Jr., Scott C, Langer C, Komaki R, Lee J, Hauser B, et al. (2000) Phase III Comparison of Sequential Vs. Concurrent Chemoradiation for Patients with Unresected Stage III Non Small Cell Lung Cancer: Initial Report of RTOG 9410, Proc ASCO, 19:484aGoogle Scholar
  11. DeGersem WRT, Derycke S, DeWagter C and DeNeve WCJ (2000) Optimization of beam weights in conformal radiotherapy planning of stage III non small cell lung cancer: Effects on the therapeutic ratio. Int J Radiat Oncol Biol Phys 47(1):255–60CrossRefPubMedGoogle Scholar
  12. Derycke S, DeGersem WR, Van Dyuse BBR and De Neve WCJ (1998) Conformal radiotherapy of Stage III non-small cell lung cancer: a class solution involving non-coplanar intensity-modulated beams. International Journal of Radiation Oncology, Biology, Physics 41(4):771–7Google Scholar
  13. Dubray B, Livartowski A, Beuzeboc P, Pouillart P and Cosset JM (1995) Combined chemoradiation for locally advanced non-small cell lung cancer. J Infus Chemotherapy 5:195–6Google Scholar
  14. Emami, B. (1996), Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiation Oncol 6:92–7Google Scholar
  15. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–22PubMedGoogle Scholar
  16. Emami B, Scott C, Byhardt R, Graham MV, Andras EJ, John M, et al. (1996) The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis. Int J radiation Oncol Biol Phys 36(Suppl 1.):209CrossRefGoogle Scholar
  17. Fletcher G (1973) Clinical dose-response curves of human malignant epithelial tumors. Br J Radiol 46:1PubMedGoogle Scholar
  18. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. (1999) Phase III Study of Concurrent Vs. Sequential Thoracic Radiotherapy in Combination with Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non-Small Cell Lung Cancer. J. Clin. Oncol 17:2692–9PubMedGoogle Scholar
  19. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gunerlock P, Kuebler JP, Bearden JD, 3rd, Crowley J, Livingston R, SWOG (2003) Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival. J Clin Oncol 21:2004–2010CrossRefPubMedGoogle Scholar
  20. Goldstein HM, Rogers LF, Fletcher GH and GD Dodd (1975) Radiological manifestations of radiation-induced injury to the normal upper gastrointestinal tract. Radiology, 117:135–40PubMedGoogle Scholar
  21. Graham MV, Matthews JW, Harms WB, Emami B, Glazer HS and JA Purdy (1994) Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys 29:1105–17PubMedGoogle Scholar
  22. Hayman JA, Martel MK, Ten Haken RK, Normolle DP, Todd RF, Littles JF, et al. (2001) Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: Update of a Phase I trial. J Clin Oncol 19:127–36PubMedGoogle Scholar
  23. Hirota S, Tsujino K, Endo M, Kotani Y, Satouchi M, Kado T, et al. (2001) Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel radiotherapy. Int. J. Radiat. Oncol. Biol. Phys 51:291–5CrossRefPubMedGoogle Scholar
  24. Hirota, S, Tsujino K, Hishikawa Y, Watanabe H, Kono K, Soejima T, et al. (2001) Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies. Radiotherapy and Oncology 58:273–8CrossRefPubMedGoogle Scholar
  25. Ito H, Meistrich ML, Barkley HT Jr (1986) Thames HD Jr., Milas L. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721. Int J Radiation Oncology Biol Phys 12(2):211–9Google Scholar
  26. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, et al. (2002) Randomized Phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage I-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(suppl 1):46–9CrossRefPubMedGoogle Scholar
  27. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, et al. (1996) The impact of overall treatment time on the results of radiotherapy for non-small cell lung carcinoma. Int J Radiation Oncology Biol Phys 34:315–22CrossRefGoogle Scholar
  28. Langer CJ (1999) Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Sem Rad Oncol, 9:108–16Google Scholar
  29. Lepke RA and HI Libshitz (1983) Radiation-induced injury of the esophagus. Radiology, 148:375–8PubMedGoogle Scholar
  30. Maguire, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine P, et al. (1999) Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45(1):97–103CrossRefPubMedGoogle Scholar
  31. McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Drummond RG, Frank AR, et al. (1997) Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol 15:1239–43PubMedGoogle Scholar
  32. Michalowski A and Hornsey S (1986) Assays of damage to the alimentary canal. Br J Cancer, 53 1986;suppl VII:1–6PubMedGoogle Scholar
  33. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R and R Byhardt (2003) Phase III study of amifostine in patients with locally advanced non-small cell lung cancer receiving intensive chemoradiation: Radiation Therapy Oncology Group 98-01. Proc ASCO, 22:636, abstr# 2459Google Scholar
  34. Phillips TL and G Ross (1974) Time-dose relationships in the mouse esophagus. Radiology, 113:435–40PubMedGoogle Scholar
  35. Rowland M and Tozer T (1995) Assessment of Area Under the Curve. In: Clinical Pharmacokinetics. Concepts and Applications, 3rd Edition. Williams and Wilkins, Baltimore, Philadelphia, Hong Kong and London: 469–72Google Scholar
  36. Saunders MI, Dische S, Barrett A, Parmar MKB, Harvey A and Gibson D (1996) Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: an interim report. Br J Cancer 73:1455–62PubMedGoogle Scholar
  37. Singh AK, Lockett MA and Bradley JD (2003) Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 55:337–41CrossRefPubMedGoogle Scholar
  38. Stickle RL, Epperly MW, Klein E, Bray J, Greenberger J (1999) Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. Radiat Oncol Invest 7:204–17CrossRefGoogle Scholar
  39. Umsawasdi T, Valdivieso M, Barkley HT, Booser DJ, Chiuten DF, Murphy WK, et al. (1985) Esophageal complications from combined chemoradiotherapy cyclophosphamide + adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Rad Oncol Biol Phys, 11:511–9Google Scholar
  40. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR (2002) A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol 20:4191–4198CrossRefPubMedGoogle Scholar
  41. Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M, et al. (1999) Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: A multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys 44:327–31CrossRefPubMedGoogle Scholar
  42. Werner-Wasik M, Pequignot E, Leeper D, Hauck W and Curran W (2000) Predictors of Severe Esophagitis Include Use of Concurrent Chemotherapy, But Not the Length of Irradiated Esophagus: A Multivariate Analysis of Patients with Lung Cancer Treated with Non-Operative Therapy. Int. J. Radiat. Oncol. Biol. Phys 48:689–96CrossRefPubMedGoogle Scholar
  43. Werner-Wasik M, Axelrod RS, Friedland DP, Hauck W. Rose LJ, Chapman AE, et al. (2001) Preliminary Report on Reduction of Esophagitis by Amifostine in Patients with Non-Small-Cell Lung Cancer Treated with Chemoradiotherapy. Clinical Lung Cancer 2(4):284–9PubMedGoogle Scholar
  44. Werner-Wasik M, Axelrod SA, Friedland DP, Hauck W, Rose LJ, Chapman AE, et al. (2002) Phase II trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemotherapy. Semin Radiation Oncol 12(suppl 1)34–9CrossRefGoogle Scholar
  45. Werner-Wasik M, C Scott, Curran WJ Jr., and Byhardt R. (2002) Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy (RT) and chemotherapy: A multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database. Proc ASCO 21:299a, abstract #1192Google Scholar
  46. Werner-Wasik M, C Scott, B Movsas, C Langer, L Sarna, N Nicolau, R Komaki, M Machtay, C Smith, R Axelrod and R Byhardt (2003) A phase III randomized study of ami-fostine mucosal protection for patients with favorable prognosis inoperable stage II-IIIA/B NSCLC receiving sequential induction and concurrent hyperfractionated radiotherapy with paclitaxel and carboplatin: Results of the RTOG 98-01 study. Int J Radiation Oncol Phys 57(suppl):S216, abstr #152CrossRefGoogle Scholar
  47. Xiao Y, Werner-Wasik M, Michalski D, Houser C, Bednarz G, Curran W Jr., et al. (2002) Comparison of three IMRT-based treatment techniques allowing partial esophagus sparing in patients receiving thoracic radiation therapy for lung cancer. In American Society for Therapeutic Radiology and Oncology (ASTRO). Int J Radiat Oncol Biol Phys, 54(2):153 (suppl), abstract#262Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Maria Werner-Wasik
    • 1
  1. 1.Department of Radiation Oncology, Kimmel Cancer Center of Jefferson Medical CollegeThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations